This article, “Unveiling the Potential of Antibody-Drug Conjugates,” is an excellent industry review that provides a panoramic view of the hot field of Antibody-Drug Conjugates (ADCs). Next, we will journey from history to the future, delving into molecular mechanisms and clinical practices, connecting textbook knowledge to cutting-edge research. A Precision Guided “Trojan Horse”: An In-Depth … Read more
In 2024, the global antibody drug market is expected to experience explosive growth. According to IQVIA, global spending on biopharmaceuticals is projected to exceed $892 billion by 2028, with antibody drugs holding a significant share. In the fields of oncology and autoimmune diseases, three major technological routes—bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and proteolysis-targeting chimeras … Read more
Please click the “Bio New Thinking” above to follow for more exciting content! Introduction With the continuous improvement of biopharmaceutical research and clinical research levels, the research and application of Antibody-Drug Conjugates (ADCs) have been increasing. ADCs are mainly composed of antibodies, linkers, and small molecule toxins, combining high targeting specificity with high cytotoxicity. However, … Read more
In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that it is possible to find and develop drugs that specifically target the unique structural features of pathogens, killing only the pathogens without affecting normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target … Read more
Atypical hemolytic uremic syndrome (aHUS) is a type of complement-mediated thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and multi-organ damage as typical manifestations, with infection and pregnancy being the main triggers.[1] The condition of aHUS is usually quite critical. In the pre-complement treatment era, the mortality rate during the acute phase was … Read more
IDC2023 Fifth Chemical Innovation Drug and Small Molecule Conjugate Drug R&D Forum is coming with 10 major sections over 2 days, 80+ Speakers and 1200 guests gathering in Suzhou to discuss: chemical innovation drugs, modified new drugs, ADCs, small molecule conjugates, peptide conjugates, and more. Cooperation hotline: Li Xinxin 15800452389. Click the image to view … Read more
Following the era of chemotherapy, targeted therapy, and immunotherapy, cytotoxic drugs conjugated with targeted monoclonal antibodies have opened a new era in tumor treatment with the ADC drug class, achieving remarkable results. They have now become a significant category of new drugs in cancer treatment both domestically and internationally. So what exactly are ADC drugs? … Read more
Source: Beike Society Antibody-drug conjugates (ADCs) have become a popular avenue in tumor treatment in recent years, typically covalently linking a monoclonal antibody (mAb) to a cytotoxic drug (payload) via a chemically synthesized linker. ADCs combine the advantages of highly specific targeting capabilities with potent killing effects, achieving precise and efficient elimination of cancer cells. … Read more
This conference is themed “Innovative Processes, Achieving the Future of the Pharmaceutical Industry,” featuring one keynote session and three parallel sessions, gathering over 50 professional speakers from the fields of antibodies, ADCs, GLP-1, and peptides. It focuses on downstream processes and advanced separation and purification techniques, discussing the future of the pharmaceutical industry! Known as … Read more
Introduction by Good Doctor The adenoid, also known as the pharyngeal tonsil, is located at the junction of the nasopharynx and the posterior wall of the pharynx. Like the tonsils, it is a part of the lymphatic tissue and plays an important role in the immune function of the body. The ear, nose, and throat … Read more